EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Ye Qiu, Xixi Lin iD, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis iD

Molecular Oncology · 2026-07 · 20 (7) · 1814-1834

DOI: 10.1002/1878-0261.70240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 19.03.2026. Verfasst von Ye Qiu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Radiation Biology, Department of Radiation Therapy, University Hospital Essen, University of Duisburg-Essen, Germany. Hauptthemen laut MEDLINE: Cisplatin, DNA Breaks, Double-Stranded, DNA Repair, Cell Cycle. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Wirtschaft und Technologie (BMWi), Deutscher Akademischer Austausch Dienst, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA double‐strand breaks (DSBs) generated from collisions of DNA replication forks with cisplatin‐induced interstrand crosslinks underpin cisplatin cytotoxicity. Yet, the impact of cell‐cycle‐dependent cisplatin–DNA adduct (CDA) formation on cell cycle progression and interactions with DNA replication remain incompletely characterized. Also, although cisplatin enhances tumor response to ionizing radiation (IR), the underpinning radiosensitizing mechanisms remain unresolved. Here, we close this void and analyze CDAs (GpG crosslinks) and DSB (γH2AX foci) induction and repair in a strictly cell‐cycle‐dependent manner. We report for the first time that CDAs form in a dose‐ and time‐dependent manner in all cell cycle phases, whereas DSBs emerge only in S‐phase. Repair of IR‐induced DSBs remains largely unaffected by CDAs in G 1 , S, and G 2 phases, but is inhibited when S‐phase‐treated cells progressed to G 2 . Radiosensitization occurs after prolonged cisplatin exposure, likely owing to G 2 ‐phase accumulation and lesion evolution from S‐phase, thus impairing repair of IR‐induced DSBs. Cisplatin fails to radiosensitize quiescent (G 0 ) cells. In summary, CDA formation is similar across the cell cycle, but DSBs form only in S‐phase. Whereas CDAs fail to interfere with repair of IR‐induced DSBs, progression‐dependent repair disruptions cause radiosensitization. Elucidation of the underpinning mechanisms may help to design improved cisplatin–radiation schedules for more efficacious therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinDNA Breaks, Double-StrandedDNA RepairCell CycleRadiation-Sensitizing AgentsRadiation ToleranceHumansDNA AdductsCell Line, TumorHistonesDNA Replication

Stichwörter der Autor:innen

DNA double‐strand breaksDNA repaircell cyclecisplatincisplatin‐DNA adductsradiosensitization

Substanzen

CisplatinDNA AdductsRadiation-Sensitizing AgentsHistonescisplatin-DNA adduct

Autor:innen und Institutionen

  • Division of Experimental Radiation Biology, Department of Radiation Therapy, University Hospital Essen, University of Duisburg-Essen, Germany.
  • Institute of Medical Radiation Biology, University Hospital Essen, University of Duisburg-Essen, Germany.
  • Institute of Cell Biology, University Hospital Essen, Germany.
  • Radiation Biology Laboratory, Department of Radiotherapy and Radiation Oncology, University Hospital Bonn, Germany.
  • German Cancer Consortium (DKTK), Partner Site University Hospital Essen, German Cancer Research Center (DKFZ), Germany.

ORCID-Profile: Xixi Lin, George Iliakis

Förderung

  • Bundesministerium für Wirtschaft und Technologie (BMWi)
  • Deutscher Akademischer Austausch Dienst
  • Deutsche Forschungsgemeinschaft
  • Bundesministerium für Forschung Technologie und Raumfahrt (BMFTR)
  • Deutscher Akademischer Austausch Dienst Kairo
  • Bundesministerium für Bildung und Forschung

Zitieren

APA

Qiu, Y., Lin, X., Mladenov, E., Mladenova, V., Thomale, J., Sak, A., Wang, Y., Deng, Y., Gkika, E., Stuschke, M., & Iliakis, G. (2026). Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization. Molecular Oncology, 20(7), 1814-1834. https://doi.org/10.1002/1878-0261.70240

Vancouver

Qiu Y, Lin X, Mladenov E, Mladenova V, Thomale J, Sak A, et al. Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization. Molecular Oncology. 2026;20(7):1814-1834. doi:10.1002/1878-0261.70240

BibTeX
@article{Qiu2026,
  author = {Qiu, Ye and Lin, Xixi and Mladenov, Emil and Mladenova, Veronika and Thomale, Jürgen and Sak, Ali and Wang, Yao and Deng, Yunxuan and Gkika, Eleni and Stuschke, Martin and Iliakis, George},
  title = {Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {7},
  pages = {1814--1834},
  doi = {10.1002/1878-0261.70240}
}
Kostenlos starten →